| Not Yet Recruiting | Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Acti NCT07526298 | IRCCS San Raffaele | — |
| Not Yet Recruiting | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients Wit NCT07392528 | Tianjin Huanhu Hospital | EARLY_Phase 1 |
| Recruiting | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD1 NCT06939166 | Tianjin Huanhu Hospital | EARLY_Phase 1 |
| Recruiting | Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resi NCT07202494 | Assistance Publique Hopitaux De Marseille | — |
| Recruiting | Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder NCT06763848 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Recruiting | The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders NCT06620809 | Tongji Hospital | Phase 1 |
| Not Yet Recruiting | Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. NCT06485232 | Xuanwu Hospital, Beijing | EARLY_Phase 1 |
| Recruiting | Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligoden NCT06865274 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Active Not Recruiting | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD NCT06724809 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) NCT06413654 | Shanghai Jiaolian Drug Research and Development Co., Ltd | Phase 2 / Phase 3 |
| Unknown | A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders NCT06212245 | Hansoh BioMedical R&D Company | Phase 4 |
| Recruiting | Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases NCT06541626 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Enrolling By Invitation | Normal Chinese Lifespan Brain Charts Initiative (NCLBCI) NCT06643858 | Beijing Tiantan Hospital | — |
| Unknown | Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders NCT06068829 | Feng Jinzhou | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease ( NCT06697535 | Guangzhou JOYO Pharma Co., Ltd | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) NCT05730699 | Biocad | Phase 3 |
| Completed | Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol NCT05871658 | Yuanqi Zhao,MD | N/A |
| Recruiting | MS-ResearchBiomarkerS NCT05204459 | Cedars-Sinai Medical Center | — |
| Completed | An Open Label Study of the Effects of SHR1459 in NMOSDs Patients NCT04670770 | Reistone Biopharma Company Limited | Phase 2 |
| Completed | A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders NCT04146285 | Bio-Thera Solutions | Phase 1 |
| Completed | An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit NCT04388072 | First Affiliated Hospital of Fujian Medical University | — |
| Unknown | Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders NCT04101058 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Terminated | A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spect NCT03330418 | RemeGen Co., Ltd. | Phase 3 |
| Completed | Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility NCT07164924 | University Hospital, Clermont-Ferrand | — |
| Completed | Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders NCT03350633 | Tianjin Medical University General Hospital | Phase 2 / Phase 3 |
| Completed | A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD NCT03062579 | Fu-Dong Shi | Phase 1 / Phase 2 |
| Unknown | Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients NCT02809079 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders NCT02836327 | Chinese PLA General Hospital | — |
| Unknown | The French Multiple Sclerosis Registry NCT02889965 | Hospices Civils de Lyon | — |
| Completed | The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMA NCT02850705 | Hospices Civils de Lyon | — |
| Unknown | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders NCT02021825 | Xuanwu Hospital, Beijing | Phase 4 |